1
Clinical Trials associated with JCXH-221A PHASE 1/2 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BROADLY PROTECTIVE mRNA VACCINE JCXH-221 AGAINST SARS-CoV-2 INFECTION AND DISEASES
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are:
To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects
To identify an optimal dose for the JCXH-221 vaccine in healthy adult subjects
To assess the humoral immunogenicity of the JCXH-221 vaccine in healthy adult subjects
To characterize the cellular immunogenicity of the JCXH-221 vaccine in healthy adult subjects
Participants for Phase I will be randomized to either JCXH-221 or placebo. In Phase 2, participants will be randomized to either JCXH-221 or a FDA approved Active comparator.
100 Clinical Results associated with JCXH-221
100 Translational Medicine associated with JCXH-221
100 Patents (Medical) associated with JCXH-221
100 Deals associated with JCXH-221